OncoCyte (NAS:OCX) Goodwill

: $18.68 Mil (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. OncoCyte's goodwill for the quarter that ended in Sep. 2022 was $18.68 Mil.

OncoCyte Goodwill Historical Data

The historical data trend for OncoCyte's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Goodwill

9.19

18.68

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Goodwill																18.43	18.68	18.68	18.68	18.68

OncoCyte Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

OncoCyte (NAS:OCX) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

OncoCyte's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill-to-Asset (A: Dec. 2021 )	=	Goodwill	/	Total Assets
	=	18.68	/	159.563
	=	0.12

OncoCyte's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Goodwill-to-Asset (Q: Sep. 2022 )	=	Goodwill	/	Total Assets
	=	18.68	/	157.344
	=	0.12

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

OncoCyte Goodwill Related Terms

Thank you for viewing the detailed overview of OncoCyte's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Goodwill

Comparable Companies

Traded in Other Exchanges

0KCC:UK 7OC:Germany 7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Paulsen Gisela	officer: Chief Operating Officer	5505 ENDEAVOR LANE MADISON WI 53719
Yu Li	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L.	director	C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T.	officer: Chief Medical Officer	15 CUSHING IRVINE CA 92618
Kamen Efrem	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda	director	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury	director	5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P	officer: Chief Operating Officer	C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S	officer: Chief Financial Officer	ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K.	officer: Sr VP, Research & Development	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M	director	1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C	10 percent owner